NBD-557
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


NBD-557
Description:
NBD-557 is a potentially HIV-1 inhibitor. IC50 Value: Target: HIV NBD-557, is small molecule organic compounds with drug-like properties. It showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels. A systematic study showed that NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-557 potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, respectively, indicating that its anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that NBD-557 bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4. NBD-557 was active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that NBD-557 can potentially be further modified to become potent HIV-1 entry inhibitors.UNSPSC:
12352005Target:
HIVType:
Reference compoundRelated Pathways:
Anti-infectionApplications:
COVID-19-anti-virusField of Research:
InfectionAssay Protocol:
https://www.medchemexpress.com/NBD-557.htmlPurity:
99.41Solubility:
DMSO : 10 mg/mL (ultrasonic)Smiles:
O=C(C(NC1CC(C)(NC(C)(C1)C)C)=O)NC2=CC=C(C=C2)BrMolecular Formula:
C17H24BrN3O2Molecular Weight:
382.30References & Citations:
[1]Arne Schön, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006 Sep 12;45 (36) :10973-80.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
HIV-1CAS Number:
[333352-59-3]
